GRDN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Guardian Pharmacy Services Inc (GRDN) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown strong financial performance and positive analyst sentiment, the lack of significant trading signals, recent price decline, and neutral trading sentiment suggest waiting for a more favorable entry point.
The stock's MACD is positive but contracting, RSI is neutral at 51.62, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock has recently declined 3.01% in the regular market, and the next support level is at 32.092, with resistance at 37.429.
Strong Q4 financial performance with revenue up 17.44% YoY, net income up 75.19% YoY, and EPS up 72.22% YoY. Analysts have raised price targets to $38 and maintain positive ratings, citing sustainable growth drivers and market positioning.
No recent news or significant trading activity from hedge funds, insiders, or Congress. The stock has a historical trend of potential short-term declines (-5.85% in the next month).
In Q4 2025, revenue increased by 17.44% YoY to $397.6M, net income rose by 75.19% YoY to $20.92M, EPS grew by 72.22% YoY to 0.31, and gross margin improved by 8.48% YoY to 21.5%.
Analysts from Truist and Oppenheimer raised their price targets to $38, citing strong organic trends, improved vaccine profitability, and sustainable growth drivers. Both maintain a Buy/Outperform rating.
